American Society of Clinical OncologyPhase II Trial of Pembrolizumab + Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as SLT for Rel/Ref Classical Hodgkin Lymphoma (cHL)

Second-line therapy with pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) is a highly effective and well-tolerated regimen that can efficiently bridge patients with rel/ref cHL to high-dose therapy and autologous hematopoietic cell transplantation (HDT/AHCT).

American Society of HematologyTisagenlecleucel vs. SOC as 2L Therapy of Primary R/R Aggressive B-Cell NHL: Analysis of the Phase III Belinda Study

Adults with confirmed R/R aNHL within 12 months after first-line (1L) chemo-immunotherapy were eligible for the randomized Phase III study, which demonstrated that tisagenlecleucel (tisa-cel) as second-line (2L) treatment in R/R aNHL patients did not have a higher event-free survival (EFS) vs. the standard-of-care (SOC). Read this late-breaking abstract from the ASH Annual Meeting & […]

American Society of HematologyThe POLARIX Study: Polatuzumab Vedotin w. Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) vs. R-CHOP Therapy in Patients w. Previously Untreated DLBCL

A late-breaking abstract from the ASH Annual Meeting & Exhibition. In this double-blind, placebo-controlled, international study of 879 patients (median age: 65 (range 19–80) years; IPI 3–5 (62%)), the pola-R-CHP combination demonstrated a 27% reduction in the relative risk of disease progression, relapse, or death compared with R-CHOP, with a similar safety profile in the […]

Millennium Medical PublishingDA-R-EPOCH vs. R-CHOP in DLBCL: How Do We Choose?

DLBCL is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. This has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment paradigm in recent years, as several DLBCL subtypes have inferior survival after standard R-CHOP therapy. So how do you choose? In this review the authors conclude with proposed clinical management […]

Millennium Medical PublishingEvolving Strategies for the Management of Transformed Lymphoma

Clinical Advances in Hematology & Oncology talks with Sonali M. Smith, MD, an Elwood V. Jensen Professor in Medicine and Chief, Section of Hematology/Oncology at the University of Chicago, about all things transformed lymphoma, including risk factors, distinguishing characteristics, pathogenesis, traditional treatment approaches, treatment goals, new treatment strategies, and other promising areas of research.

American Society of HematologyCognitive Decline Observed Six Months After Chemotherapy in Patients With Lymphoma

Publication: ASH Clinical NewsOriginal Source: Journal of the National Care InstituteDesign: Assessment of longitudinal changes in memory, attention, and executive function in men and women with lymphoma (n=248; 62.5% male) prior to and six months after initiation of chemotherapy. A group of age- and sex-matched people without cancer was used as a control arm (n=212; […]

American Society of HematologyActivity of mRNA COVID-19 Vaccines in Patients with Lymphoid Malignancies

Publication: Blood AdvancesStudy Design: Prospective study with unmatched health care workforce control group, receiving either Moderna or Pfizer COVID vaccination.Study Population: 23 patients with CLL (61%), lymphoma (39%) (including DLBCL), MCL (13%) and 4% with less common lymphomas.Outcome: Lymphoma patients had significantly lower anti-S IgG titers 28 days post-vaccination compared with controls. Related Article: Efficacy […]

American Society of HematologyClonal Hematopoiesis in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates […]